Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2023-08-23
2023-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of CM310 in Subjects With Seasonal Allergic Rhinitis
NCT06171074
Study of CM310 in Subjects With Allergic Rhinitis
NCT05908032
A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
NCT05470647
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
NCT06300203
Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis
NCT06577077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM310
Subcutaneous injection
CM310
IL-4Rα monoclonal antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM310
IL-4Rα monoclonal antibody
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understand the study and sign the Informed Consent Form voluntarily.
* Take effective contraception measures throughout the study period.
Exclusion Criteria
* Allergies to drugs with IL-4Rα monoclonal antibody or drug components of CM310.
* Plan to participate in other studies during this clinical trial.
* With malignant or benign tumors of the nasal cavity.
* Other reasons the researcher believes that the subject is not suitable to participate in this study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luo Zhang
Role: PRINCIPAL_INVESTIGATOR
Beijing Tong-Ren hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tong-Ren hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM310-107107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.